Author Correction: PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma (Nature Communications, (2020), 11, 1, (6262), 10.1038/s41467-020-19810-w)

Antoni Ribas*, Alain Algazi, Paolo A. Ascierto, Marcus O. Butler, Sunandana Chandra, Michael Gordon, Leonel Hernandez-Aya, Donald Lawrence, Jose Lutzky, Wilson H. Miller, Katie M. Campbell, Bruno Delafont, Shannon Marshall, Nancy Mueller, Caroline Robert

*Corresponding author for this work

Research output: Contribution to journalComment/debatepeer-review

Abstract

There was an error in the original version of this Article. A table describing the patient characteristics and the sample collection was not included in the paper. This table is now included as Supplementary Data 1 and the first sentence of the Results section has been amended to state ‘Between December 2013 and April 2015, 99 patients were screened. Sixty-eight patients were enrolled from 11 study centers (Supplementary Fig. 1, Supplementary Data 1), with 31 patients subsequently excluded due to screening failures’. The PDF and HTML versions of the Article have been updated.

Original languageEnglish (US)
Article number5022
JournalNature communications
Volume12
Issue number1
DOIs
StatePublished - Dec 2021

ASJC Scopus subject areas

  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Physics and Astronomy(all)

Fingerprint

Dive into the research topics of 'Author Correction: PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma (Nature Communications, (2020), 11, 1, (6262), 10.1038/s41467-020-19810-w)'. Together they form a unique fingerprint.

Cite this